Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 5,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 5,000 shares of the business’s stock in a transaction on Friday, February 6th. The stock was sold at an average price of $29.04, for a total value of $145,200.00. Following the transaction, the insider owned 740,188 shares in the company, valued at approximately $21,495,059.52. This trade represents a 0.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock opened at $27.93 on Wednesday. The stock has a market cap of $1.66 billion, a PE ratio of -15.18 and a beta of 0.34. The stock has a 50-day moving average of $21.78 and a two-hundred day moving average of $20.77. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $30.22.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enliven Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $41.00.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors have recently bought and sold shares of the business. AXQ Capital LP acquired a new stake in Enliven Therapeutics during the 4th quarter valued at approximately $219,000. Intech Investment Management LLC raised its holdings in shares of Enliven Therapeutics by 15.6% during the fourth quarter. Intech Investment Management LLC now owns 16,729 shares of the company’s stock worth $258,000 after purchasing an additional 2,256 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Enliven Therapeutics during the fourth quarter valued at $95,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Enliven Therapeutics by 30.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,818 shares of the company’s stock worth $508,000 after purchasing an additional 5,754 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.